Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the Society for Immunotherapy of Cancer 36th Annual Meeting
Celularity Inc. - Class A (CELU)
Company Research
Source: GlobeNewswire
FLORHAM PARK, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) presented preclinical data on the development of its novel allogeneic genetically modified human placental CD34+ derived NK cell therapeutic program CYNK-101. Celularity reported its findings in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting held in Washington, D.C., November 10-14, 2021. Poster 159: “Developing placental CD34+-derived natural killer cells with high affinity cleavage resistant CD16 (CYNK-101) and Cetuximab for enhanced therapy of EGFR+ non-small cell lung and head and neck cancers” Highlights: CYNK-101 is a cryopreserved off the shelf allogeneic NK cell product, overexpressing a high IgG binding affinity, proteinase cleavage resistant, CD16 variant. The results demonstrate the synergistic effect of combining CYNK-101 with Cetuximab to drive antibody dependent cellular cytotoxicity activity against EGFR+ tumors. Further develop
Show less
Read more
Impact Snapshot
Event Time:
CELU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELU alerts
High impacting Celularity Inc. - Class A news events
Weekly update
A roundup of the hottest topics
CELU
News
- Celularity Inc. to Host Investor and Analyst Research & Development Day [Yahoo! Finance]Yahoo! Finance
- Celularity Inc. to Host Investor and Analyst Research & Development DayGlobeNewswire
- Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing [Yahoo! Finance]Yahoo! Finance
- Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K FilingGlobeNewswire
- Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024 [Yahoo! Finance]Yahoo! Finance
CELU
Earnings
- 1/2/24 - Miss
CELU
Sec Filings
- 4/22/24 - Form 8-K
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- CELU's page on the SEC website